A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease.

A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease.
Curr Med Chem. 2018 May 16;:
Authors: Korabecny J, Spilovska K, Mezeiova E, Benek O, Juza R, Kaping D, Soukup O
Abstract
Alzheimer's disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden. This review presents the overview of donepezil-related compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.
PMID: 29768996 [PubMed - as supplied by publisher]

Source: Current Medicinal Chemistry - May 16, 2018 Category: Chemistry Authors: Korabecny J, Spilovska K, Mezeiova E, Benek O, Juza R, Kaping D, Soukup O Tags: Curr Med Chem Source Type: research